2016 - Fellow of the American Association for the Advancement of Science (AAAS)
2010 - Fellow of the American Statistical Association (ASA)
Yu Shyr mainly focuses on Internal medicine, Cancer research, Surgery, Gastroenterology and Endocrinology. His Internal medicine research includes elements of Oncology and Cardiology. His Cancer research study combines topics in areas such as Endothelial stem cell, Transforming growth factor, Transforming growth factor beta and CD8.
His Surgery study integrates concerns from other disciplines, such as Incidence and Confidence interval. His research investigates the link between Gastroenterology and topics such as Colorectal cancer that cross with problems in Adenoma and Odds ratio. His Endocrinology research is multidisciplinary, relying on both Immune system and C-reactive protein.
Yu Shyr mainly investigates Internal medicine, Cancer research, Cancer, Oncology and Pathology. The various areas that he examines in his Internal medicine study include Gastroenterology, Endocrinology and Surgery. His work on Cancer research is being expanded to include thematically relevant topics such as Carcinogenesis.
His work carried out in the field of Oncology brings together such families of science as Carboplatin, Regimen, Paclitaxel, Breast cancer and Adenocarcinoma. His Pathology study frequently draws connections between related disciplines such as Metastasis. His Hemodialysis research incorporates elements of Prospective cohort study and Kidney disease.
Internal medicine, Cancer research, Cancer, Oncology and Computational biology are his primary areas of study. Many of his studies on Internal medicine apply to Endocrinology as well. His work in Cancer research covers topics such as Phases of clinical research which are related to areas like Cediranib.
His work in the fields of Cancer, such as Breast cancer, overlaps with other areas such as Severe acute respiratory syndrome coronavirus 2 and 2019-20 coronavirus outbreak. The Oncology study combines topics in areas such as Adverse effect, Clinical endpoint, Proportional hazards model, Triple-negative breast cancer and Adenocarcinoma. The concepts of his Computational biology study are interwoven with issues in Bioinformatics, RNA, Genotyping, Single-nucleotide polymorphism and DNA sequencing.
His primary areas of study are Internal medicine, Computational biology, Cancer research, Gene and Cancer. His Internal medicine research integrates issues from Endocrinology, Oncology and Cardiology. The study incorporates disciplines such as Breast cancer, Triple-negative breast cancer, Metastasis and Gene expression profiling in addition to Oncology.
He studies Cancer research, focusing on Melanoma in particular. Yu Shyr focuses mostly in the field of Gene, narrowing it down to matters related to Pathology and, in some cases, Retinoblastoma, PTEN and Mutation. His Cancer research is multidisciplinary, incorporating perspectives in Lung cancer, Cisplatin and Statistical significance.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
Brian D. Lehmann;Joshua A. Bauer;Xi Chen;Melinda E. Sanders.
Journal of Clinical Investigation (2011)
Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
Jeffrey A. Sosman;Kevin B. Kim;Lynn Schuchter;Rene Gonzalez.
The New England Journal of Medicine (2012)
Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage.
J D Morrow;B Frei;A W Longmire;J M Gaziano.
The New England Journal of Medicine (1995)
Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
Mark G. Kris;Bruce E. Johnson;Lynne D. Berry;David J. Kwiatkowski.
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.
Nicole M. Kuderer;Toni K. Choueiri;Dimpy P. Shah;Yu Shyr.
The Lancet (2020)
Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis
Li Yang;Laura M. DeBusk;Koari Fukuda;Barbara Fingleton.
Cancer Cell (2004)
Reproducibility of the diagnosis of dysplasia in Barrett esophagus: A reaffirmation
Elizabeth Montgomery;Mary P. Bronner;John R. Goldblum;Joel K. Greenson.
Human Pathology (2001)
Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection
Brian D. Lehmann;Bojana Jovanović;Xi Chen;Monica V. Estrada.
PLOS ONE (2016)
Proteomic patterns of tumour subsets in non-small-cell lung cancer.
Kiyoshi Yanagisawa;Yu Shyr;Baogang J Xu;Pierre P Massion.
The Lancet (2003)
Regional cerebral activation in irritable bowel syndrome and control subjects with painful and nonpainful rectal distention.
Howard Mertz;Victoria Morgan;Gordon Tanner;David Pickens.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: